Adaptimmune Therapeutics PLC (ADAP)
1.04
-0.01
(-0.95%)
USD |
NASDAQ |
May 28, 16:00
1.025
-0.02
(-1.44%)
After-Hours: 20:00
Adaptimmune Therapeutics Cash from Financing (Quarterly): 29.24M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 29.24M |
December 31, 2023 | 0.074M |
September 30, 2023 | 0.596M |
June 30, 2023 | 0.014M |
March 31, 2023 | 0.196M |
December 31, 2022 | 1.403M |
September 30, 2022 | 1.452M |
June 30, 2022 | 9.977M |
March 31, 2022 | 0.035M |
December 31, 2021 | 0.052M |
September 30, 2021 | 0.139M |
June 30, 2021 | 2.563M |
March 31, 2021 | 0.534M |
December 31, 2020 | 0.122M |
September 30, 2020 | 0.466M |
June 30, 2020 | 248.02M |
March 31, 2020 | 91.44M |
December 31, 2019 | 0.00 |
Date | Value |
---|---|
September 30, 2019 | 0.00 |
June 30, 2019 | 0.33M |
March 31, 2019 | 0.036M |
December 31, 2018 | 0.104M |
September 30, 2018 | 100.16M |
June 30, 2018 | 0.89M |
March 31, 2018 | 1.534M |
December 31, 2017 | 0.00 |
September 30, 2017 | 0.37M |
June 30, 2017 | 41.80M |
March 31, 2017 | 61.40M |
December 31, 2016 | 0.017M |
September 30, 2016 | 0.00 |
June 30, 2016 | 0.00 |
March 31, 2016 | 0.00 |
September 30, 2015 | 0.00 |
December 31, 2014 | -4.093M |
September 30, 2014 | 98.34M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Sep 2019
248.02M
Maximum
Jun 2020
19.33M
Average
0.398M
Median
Cash from Financing (Quarterly) Benchmarks
Biodexa Pharmaceuticals Plc | -- |
NuCana PLC | 1.758M |
Autolus Therapeutics PLC | 561.44M |
TC BioPharm (Holdings) PLC | 1.183M |
Mereo BioPharma Group PLC | -- |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -31.95M |
Cash from Investing (Quarterly) | -0.358M |
Free Cash Flow | -138.26M |
Free Cash Flow Per Share (Quarterly) | -0.1336 |
Free Cash Flow to Equity (Quarterly) | -32.31M |
Free Cash Flow to Firm (Quarterly) | -32.31M |
Free Cash Flow Yield | -60.41% |